Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients?

M. Broeders, J. Molema, N. Vermue, H. Folgering (Groesbeek, Zeist, The Netherlands)

Source: Annual Congress 2003 - Issues surrounding drug delivery
Session: Issues surrounding drug delivery
Session type: Thematic Poster Session
Number: 2988
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Broeders, J. Molema, N. Vermue, H. Folgering (Groesbeek, Zeist, The Netherlands). Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients?. Eur Respir J 2003; 22: Suppl. 45, 2988

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bronchodilator response to different doses of albuterol in asthmatic children
Source: Annual Congress 2007 - Crossroads between paediatric respiratory physiology and epidemiology
Year: 2007


The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Long acting bronchodilation of Spiriva® handihaler in COPD patients, the influence of the inhalation flow rate (IFR)
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 125s
Year: 2005

Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 43s
Year: 2001

Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


High doses inhaled salbutamol by MDI in patients with acute bronchial asthma and its cardiopulmonary effects
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Bronchodilation from formoterol and terbutaline has similar onset of action in asthmatic children
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004

The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 240s
Year: 2002

FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 840s
Year: 2006

Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients
Source: Annual Congress 2010 - COPD: management
Year: 2010


Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

High doses of inhaled formoterol have less systemic effect in asthmatic children than high doses of inhaled terbutaline
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001